## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# Form 8-K

#### **Current Report**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 13, 2005

# CORTEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-16467 (Commission File Number) 33-0303583 (I.R.S Employer Identification No.)

15241 Barranca Parkway

Irvine, California (Address of principal executive offices)

92618 (Zip Code)

Registrant s telephone number, including area code: (949) 727-3157

# Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 1.01. Entry into a Material Definitive Agreement.**

On August 13, 2005, Cortex Pharmaceuticals, Inc., a Delaware corporation (the Company), entered into a Third Amendment to Employment Agreement (the Amendment) with Roger G. Stoll, Ph.D., which amends that certain Employment Agreement by and between the Company and Dr. Stoll dated October 29, 2002, as amended (the Employment Agreement). The Employment Agreement provides for the terms of the employment of Dr. Stoll by the Company as its President, Chief Executive Officer and Chairman of the Board. The Amendment amends Section 2 of the Employment Agreement by extending the term of the Employment Agreement to August 13, 2008, which otherwise would be expiring on August 13, 2005.

#### **Item 9.01.** Financial Statements and Exhibits.

(c) Exhibits.

Exhibit Number	Description
10.1	Third Amendment to Employment Agreement dated October 29, 2002 Between Cortex
10.1	Pharmaceuticals and Roger G. Stoll, Ph.D.

# Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEX PHARMACEUTICALS, INC.

Date: August 17, 2005

By: /s/ Maria S. Messinger

Maria S. Messinger

Vice President, Chief Financial Officer

and Corporate Secretary

# EXHIBIT INDEX

Exhibit Number	Description
10.1	Third Amendment to Employment Agreement dated October 29, 2002 Between Cortex Pharmaceuticals and Roger G. Stoll, Ph.D.